Lipids-based products developer Enzymotec sets terms for $75 million IPO

By
A A A

Enzymotec, which develops lipid-based nutritional ingredients and medical foods, announced terms for its IPO on Monday. The Migdal Ha'Emeq, Israel-based company plans to raise $75 million by offering 4.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Enzymotec would command a fully diluted market value of $391 million.  

Enzymotec, which was founded in 1998 and booked $51 million in sales for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol ENZY. Enzymotec initially filed confidentially on July 10, 2013. BofA Merrill Lynch and Jefferies are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ENZY

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

100,966,220
  • $3.95 ▲ 3.40%
61,781,634
  • $7.27 ▼ 6.31%
48,540,454
  • $30.94 ▼ 4.89%
48,315,969
    $23 unch
38,436,487
  • $15.345 ▼ 1.51%
38,408,416
  • $96.1195 ▼ 2.07%
33,079,425
  • $45.4301 ▼ 1.88%
30,228,920
  • $95.42 ▼ 1.61%
As of 7/31/2014, 01:51 PM